Trend in blood serum levels of light and heavy chains of neurofilaments in infants with spinal muscular atrophy against background of the use of gene therapy

Introduction. Determination of neurofilaments (NF) levels in blood serum and CSF in children with spinal muscular atrophy (SMA) may be a promising biomarker of the severity and course of the disease, as well as a way of assessing the effectiveness of pathogenetic therapy.

The aim of the study was to determine the blood serum NF levels of in 0–24 months infants with SMA type I at the presymptomatic stage of the disease before and after gene therapy with onasemnogene abeparvovec (OA).

Materials and methods. The study included one hundred fifty five 0–24 months infants including 76 neurologically healthy children (group II), as well as 79 patients with SMA from group I (subgroup Ia — 44 infants with SMA type I, Ib — 35 infants at the presymptomatic stage of the disease) with a diagnosis of SMA. The majority of infants with type I SMA (subgroup Ia) had 2 copies of the SMN2 gene (n = 43; 97.7%), while infants from subgroup Ib (asymptomatic patients) had 3 copies (n = 31; 88.6%).

Results. The values of NF light and heavy chains in infants from group I were obtained before and after 3–6, 7–12, and 13–24 months after gene therapy with OA. The NF light chains level in the Ia subgroup before treatment was significantly higher than in the Ib subgroup (p < 0.001) and higher than in the control group (p < 0.001). The serum level of NF heavy chains in the Ia subgroup before treatment was also significantly higher than in the control group. In the Ia subgroup, there was a significant decrease (p < 0.01) in serum NF light chains 3–6 months after gene therapy (Me [Q1; Q3] — 22.97 [6.00; 48.54]) compared with the same indices before treatment (6.0 [5.92; 7.78]). Subsequently, after 7–12 months (6.15 [5.15; 7.30]) and 13–24 months (6.0 [5.7; 6.6]), stabilization of Me values was noted with a decrease in interquartile ranges. In the Ib subgroup, there was also a significant decrease (p < 0.01) in serum NF light chains levels 3–6 months after OA gene therapy (6.0 [6.00; 7.25]) compared with these indices before treatment (6.0 [6.00; 31.43]).

Conclusion. Determination of the blood serum NF light and heavy chains levels inSMA patient before and after gene therapy can be regarded as a marker of the severity of the disease and the effectiveness of treatment.

Compliance with ethical standards. Permission for conducting this study was obtained from the local ethics committee of the National Medical Research Center for Children’s Health, of the Ministry of Health of the Russian Federation (Minutes of the Local ethics committee meeting No. 10 dated 06.10.2022).

Contribution:
Fisenko D.A. — concept and design of the review, writing the text, editing;
Kuzenkova L.M. — concept and design of the review, writing the text, editing;
Kurenkov A.L. — concept and design of the review, editing;
Semikina E.L. — editing;
Uvakina E.V. — concept and design of the review, writing the text, editing;
Chernikov V.V. — statistical data processing;
Kurbatova O.V. — editing;
Komyagina T.M. — editing;
Konyashin M.V. — editing;
Popovich S.G. — editing.
All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.

Acknowledgements. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: March 20, 2025
Accepted: April 7, 2025
Published: April 30, 2025

1. Fisenko D.A., Kuzenkova L.M., Kurenkov A.L., Uvakina E.V., Popovich S.G. Neurofilaments as a biomarker of spinal muscular atrophy: review. Nevrologicheskii zhurnal imeni L.O. Badalyana. 2023; 4(3): 130–6. https://doi.org/10.46563/2686-8997-2023-4-3-130-136 https://elibrary.ru/epnbqa (in Russian)

2. Vladykina A.V., Nazarov V.D., Krasnov V.S., Koroleva E.I., Fedorova P.A., Moshnikova A.N., et al. The diagnostic significance of neurofilament heavy chains in cerebrospinal fluid in amyotrophic lateral sclerosis. Annaly klinicheskoi i eksperimental’noi nevrologii. 2021; 15(1): 43–50. https://doi.org/10.25692/ACEN.2021.1.5 https://elibrary.ru/gemjpp (in Russian)

3. Gafson A.R., Barthélemy N.R., Bomont P., Carare R.O., Durham H.D., Julien J.P., et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain. 2020; 143(7): 1975–98. https://doi.org/10.1093/brain/awaa098

4. Xu Z., Henderson R.D., David M., McCombe P.A. Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis. PLoS One. 2016; 11(10): e0164625. https://doi.org/10.1371/journal.pone.0164625

5. Wong Y.Y.M., Bruijstens A.L., Barro C., Michalak Z., Melief M.J., Wierenga A.F., et al. Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes. Neurology. 2019; 93(10): e968–74. https://doi.org/10.1212/wnl.0000000000008057

6. Körtvelyessy P., Kuhle J., Düzel E., Vielhaber S., Schmidt C., Heinius A., et al. Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré syndrome. Ann. Clin. Transl. Neurol. 2020; 7(11): 2213–20. https://doi.org/10.1002/acn3.51207

7. Nitz E., Smitka M., Schallner J., Akgün K., Ziemssen T., von der Hagen M., et al. Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. Ann. Clin. Transl. Neurol. 2021; 8(10): 2013–24. https://doi.org/10.1002/acn3.51449

8. Wurster C.D., Steinacker P., Günther R., Koch J.C., Lingor P., Uzelac Z., et al. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. J. Neurol. 2020; 267(1): 36–44. https://doi.org/10.1007/s00415-019-09547-y

9. Khalil M., Teunissen C.E., Otto M., Piehl F., Sormani M.P., Gattringer T., et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 2018; 14(10): 577–89. https://doi.org/10.1038/s41582-018-0058-z

10. Gordon B.A. Neurofilaments in disease: what do we know? Curr. Opin. Neurobiol. 2020; 61: 105–15. https://doi.org/10.1016/j.conb.2020.02.001

11. Steinacker P., Feneberg E., Weishaupt J., Brettschneider J., Tumani H., Andersen P.M., et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J. Neurol. Neurosurg. Psychiatry. 2016; 87(1): 12–20. https://doi.org/10.1136/jnnp-2015-311387

12. Brettschneider J., Petzold A., Süßmuth S.D., Ludolph A.C., Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006; 66(6): 852–6. https://doi.org/10.1212/01.wnl.0000203120.85850.54

13. De Schaepdryver M., Goossens J., De Meyer S., Jeromin A., Masrori P., Brix B., et al. Serum neurofilament heavy chains as early marker of motor neuron degeneration. Ann. Clin. Transl. Neurol. 2019; 6(10): 1971–9. https://doi.org/10.1002/acn3.50890

14. Boylan K.B., Glass J.D., Crook J.E., Yang C., Thomas C.S., Desaro P., et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2013; 84(4): 467–72. https://doi.org/10.1136/jnnp-2012-303768

15. Halbgebauer S., Steinacker P., Verde F., Weishaupt J., Oeckl P., von Arnim C., et al. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J. Neurol. Neurosurg. Psychiatry. 2022; 93(1): 68–74. https://doi.org/10.1136/jnnp-2021-327129

16. Revendova K.Z., Zeman D., Bunganic R., Karasova K., Volny O., Bar M., et al. Serum neurofilament levels in patients with multiple sclerosis: A comparison of SIMOA and high sensitivity ELISA assays and contributing factors to ELISA levels. Mult. Scler. Relat. Disord. 2022; 67: 104177. https://doi.org/10.1016/j.msard.2022.104177

17. Lin A.V. Direct ELISA. Methods Mol. Biol. 2015; 1318: 61–7. https://doi.org/10.1007/978-1-4939-2742-5_6

18. RayBiotech. ELISA vs. Immuno-PCR vs. SIMOA: Comparison of protein detection tools. Available at: https://raybiotech.com/elisa-immunopcr-simoa

19. Byrne L.M., Schultz J.L., Rodrigues F.B., van der Plas E., Langbehn D., Nopoulos P.C., et al. Neurofilament light protein as a potential blood biomarker for Huntington’s disease in children. Mov. Disord. 2022; 37(7): 1526–31. https://doi.org/10.1002/mds.29027

20. Jacobs Sariyar A., van Pesch V., Nassogne M.C., Moniotte S., Momeni M. Usefulness of serum neurofilament light in the assessment of neurologic outcome in the pediatric population: a systematic literature review. Eur. J. Pediatr. 2023; 182(5): 1941–8. https://doi.org/10.1007/s00431-022-04793-1

21. Reinert M.C., Benkert P., Wuerfel J., Michalak Z., Ruberte E., Barro C., et al. Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2020; 7(4): e749. https://doi.org/10.1212/nxi.0000000000000749

22. Ferreira-Atuesta C., Reyes S., Giovanonni G., Gnanapavan S. The evolution of Neurofilament light chain in multiple sclerosis. Front. Neurosci. 2021; 15: 642384. https://doi.org/10.3389/fnins.2021.642384

23. Depoorter A., Neumann R.P., Barro C., Fisch U., Weber P., Kuhle J., et al. Neurofilament light chain: blood biomarker of neonatal neuronal injury. Front. Neurol. 2018; 9: 984. https://doi.org/10.3389/fneur.2018.00984

24. Bayoumy S., Verberk I.M.W., Vermunt L., Willemse E., den Dulk B., van der Ploeg A.T., et al. Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges. Clin. Chem. Lab. Med. 2024; 62(7): 1252–65. https://doi.org/10.1515/cclm-2023-1311

25. Shahim P., Politis A., van der Merwe A., Moore B., Ekanayake V., Lippa S.M., et al. Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. Neurology. 2020; 95(6): e623–36. https://doi.org/10.1212/wnl.0000000000009985

26. Evers K.S., Hügli M., Fouzas S., Kasser S., Pohl C., Stoecklin B., et al. Serum Neurofilament levels in children with febrile seizures and in controls. Front. Neurosci. 2020; 14: 579958. https://doi.org/10.3389/fnins.2020.579958

27. Beerepoot S., Heijst H., Roos B., Wamelink M.M.C., Boelens J.J., Lindemans C.A., et al. Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy. Brain. 2022; 145(1): 105–18. https://doi.org/10.1093/brain/awab304

28. Toorell H., Zetterberg H., Blennow K., Sävman K., Hagberg H. Increase of neuronal injury markers Tau and neurofilament light proteins in umbilical blood after intrapartum asphyxia. J. Matern. Fetal Neonatal Med. 2018; 31(18): 2468–72. https://doi.org/10.1080/14767058.2017.1344964

29. Breville G., Sukockiene E., Vargas M.I., Lascano A.M. Emerging biomarkers to predict clinical outcomes in Guillain-Barré syndrome. Expert Rev. Neurother. 2023; 23(12): 1201–15. https://doi.org/10.1080/14737175.2023.2273386

30. Khalil M., Teunissen C.E., Lehmann S., Otto M., Piehl F., Ziemssen T., et al. Neurofilaments as biomarkers in neurological disorders — towards clinical application. Nat. Rev. Neurol. 2024; 20(5): 269–87. https://doi.org/10.1038/s41582-024-00955-x

31. Jin J., Wei J., Feng Y., Cui Y., Zhou D., Yao M., et al. Plasma neurofilament light chain in Chinese children with later-onset spinal muscular atrophy. Clin. Chem. Lab. Med. 2022; 60(10): e237–9. https://doi.org/10.1515/cclm-2022-0637

32. Gaiani A., Martinelli I., Bello L., Querin G., Puthenparampil M., Ruggero S., et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017; 74(5): 525–32. https://doi.org/10.1001/jamaneurol.2016.5398

33. Poesen K., Van Damme P. Diagnostic and prognostic performance of Neurofilaments in ALS. Front. Neurol. 2019; 9: 1167. https://doi.org/10.3389/fneur.2018.01167

34. Witzel S., Huss A., Nagel G., Rosenbohm A., Rothenbacher D., Peter R.S., et al. Population-based evidence for the use of serum Neurofilaments as individual diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis. Ann. Neurol. 2024; 96(6): 1040–57. https://doi.org/10.1002/ana.27054

35. Dalla Costa G., Martinelli V., Sangalli F., Moiola L., Colombo B., Radaelli M., et al. Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. Neurology. 2019; 92(7): e733–41. https://doi.org/10.1212/wnl.0000000000006902

36. Matsushige T., Inoue H., Fukunaga S., Hasegawa S., Okuda M., Ichiyama T. Serum neurofilament concentrations in children with prolonged febrile seizures. J. Neurol. Sci. 2012; 321(1-2): 39–42. https://doi.org/10.1016/j.jns.2012.07.043

37. Douglas-Escobar M., Yang C., Bennett J., Shuster J., Theriaque D., Leibovici A., et al. A pilot study of novel biomarkers in neonates with hypoxic-ischemic encephalopathy. Pediatr. Res. 2010; 68(6): 531–6. https://doi.org/10.1203/pdr.0b013e3181f85a03

38. Sandelius Å., Zetterberg H., Blennow K., Adiutori R., Malaspina A., Laura M., et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018; 90(6): e518–24. https://doi.org/10.1212/wnl.0000000000004932

39. Darras B.T., Crawford T.O., Finkel R.S., Mercuri E., De Vivo D.C., Oskoui M., et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann. Clin. Transl. Neurol. 2019; 6(5): 932–44. https://doi.org/10.1002/acn3.779

40. Alves C.R.R., Petrillo M., Spellman R., Garner R., Zhang R., Kiefer M., et al. Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series. Mol. Ther. Methods Clin. Dev. 2021; 23: 524–38. https://doi.org/10.1016/j.omtm.2021.10.011

41. Flotats-Bastardas M., Bitzan L., Grell C., Martakis K., Winter B., Zemlin M., et al. Paradoxical increase of neurofilaments in SMA patients treated with onasemnogene abeparvovec-xioi. Front. Neurol. 2023; 14: 1269406. https://doi.org/10.3389/fneur.2023.1269406